0001213900-22-054293.txt : 20220906 0001213900-22-054293.hdr.sgml : 20220906 20220906172124 ACCESSION NUMBER: 0001213900-22-054293 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220831 ITEM INFORMATION: Bankruptcy or Receivership ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220906 DATE AS OF CHANGE: 20220906 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clarus Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001817944 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 851231852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39802 FILM NUMBER: 221229109 BUSINESS ADDRESS: STREET 1: 555 SKOKIE BOULEVARD, SUITE 340 CITY: NORTHBROOK STATE: IL ZIP: 60062 BUSINESS PHONE: (847) 562-4300 MAIL ADDRESS: STREET 1: 555 SKOKIE BOULEVARD, SUITE 340 CITY: NORTHBROOK STATE: IL ZIP: 60062 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Acquisition Corp. DATE OF NAME CHANGE: 20200713 8-K 1 ea165390-8k_clarusthera.htm CURRENT REPORT
0001817944 false 0001817944 2022-08-31 2022-08-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K  

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 31, 2022

 

 

CLARUS THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter) 

 

 

Delaware   001-39802   85-1231852

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

555 Skokie Boulevard, Suite 340

Northbrook, Illinois

   60062
(Address of principal executive offices)    (Zip Code)

         

 

Registrant’s telephone number, including area code: (847) 871-0377

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class  Trading symbol(s)  Name of each exchange on which registered
Common Stock, par value $0.0001 per share  CRXT  *
Warrants to purchase one share of common stock at an exercise price of $11.50  CRXTW  *

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

* The registrant’s common stock and warrants began trading exclusively on the OTC Pink Marketplace on August 31, 2022 under the symbols “CRXT” and “CRXTW”, respectively.

 

 

 

 

Item 1.03. Bankruptcy or Receivership

On September 5, 2022, Clarus Therapeutics Holdings, Inc., or Clarus, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., filed voluntary petitions for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware, or the Court (Case No. 22-10845).

Clarus expects to continue its operations in the ordinary course of business without interruption during the pendency of the Chapter 11 case and pursue a structured sale of its assets pursuant to a competitive bidding and auction process. In order to maintain and continue uninterrupted ordinary course operations during the Chapter 11 case, Clarus has filed a variety of “first day” motions seeking approval from the Court for various forms of customary relief.

Clarus issued a press release announcing the filing on September 5, 2022. The press release is attached hereto as Exhibit 99.1.

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 31 2022, Clarus’ wholly-owned subsidiary entered into a Retention Compensation, PTO Payout and Amendment to Employment Agreement, or the Retention Agreements, with each of Robert Dudley, Clarus’ Chief Executive Officer, Steven Bourne, Clarus’ Chief Administrative Officer and Chief Financial Officer and Frank A. Jaeger, Clarus’ Chief Commercial Officer.

 

The Retention Agreements provide for (i) a lump sum retention payment equal to approximately $383,161, $145,965, and $167,777, to Dr. Dudley, Mr. Bourne and Mr. Jaeger, respectively, or a Retention Payment, and (ii) that each will receive a lump sum payment for such officer’s respective accrued paid time off balance as of August 31, 2022; provided that, each officer (A) agrees to remain employed until the earlier of (a) 30 days following the closing of a sale of Clarus’ assets; and (b) November 30, 2022, or the Retention Date; unless earlier terminated; and (B) agree to a release of claims.

 

Under the Retention Agreements, an officer will be required to repay the Retention Payment if he terminates his employment for any reason prior to the Retention Date, or is terminated for Cause (as defined in the officers’ existing employment agreements).

 

Additionally, the Retention Agreements amend each officer’s existing employment agreement to provide that Clarus will waive any of the officer’s post-employment noncompetition obligations and that such officer will no longer be entitled to receive severance or benefits upon either (i) the officer’s resignation for Good Reason (as defined in the officers’ existing employment agreements) or (ii) Clarus’ termination of the officer’s employment without Cause.

 

Item 8.01. Other Events

During the pendency of its Chapter 11 case, in lieu of filing quarterly reports on Form 10-Q and annual reports on Form 10-K under Section 13(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, Clarus intends to follow the procedures outlined in Exchange Act Release No. 9660 (June 30, 1972), the Securities and Exchange Commission’s, or the SEC, Staff Legal Bulletin No. 2 (April 15, 1997) and the SEC’s related no-action correspondence. Accordingly, Clarus will file with the SEC, under cover of current reports on Form 8-K, copies of the monthly financial reports required to be filed with the Court pursuant to Bankruptcy Rule 2015, as well as other material information concerning developments in its bankruptcy proceedings. Clarus will continue to comply with all other requirements of the Exchange Act, including Regulation 14A regarding the solicitation of proxies.

 

Cautionary Statements Regarding Trading in Clarus’ Securities

Clarus’ securityholders are cautioned that trading in Clarus’ securities during the pendency of the Chapter 11 case will be highly speculative and will pose substantial risks. Trading prices for Clarus’ securities may bear little or no relationship to the actual recovery, if any, by holders thereof in Clarus’ Chapter 11 case. Accordingly, Clarus urges extreme caution with respect to existing and future investments in its securities.

Cautionary Note Regarding Forward-Looking Statements

This current report on Form 8-K contains “forward-looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Clarus’ forward-looking statements in this current report on Form 8-K include, but are not limited to, statements about Clarus’ plans to sell all of its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code; Clarus’ intention to continue operations during the Chapter 11 case; Clarus’ belief that the sale process will be in the best interest of Clarus and its stakeholders; and other statements regarding Clarus’ strategy and future operations, performance and prospects among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Clarus will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clarus’ control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on Clarus’ liquidity and results of operations; changes in Clarus’ ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and the proposed auction and asset sale; the effect of the Chapter 11 filings and proposed asset sale on Clarus’ relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the proposed asset sale; uncertainty regarding obtaining bankruptcy court approval of a sale of Clarus’ assets or other conditions to the proposed asset sale; and the timing or amount of any distributions, if any, to Clarus’ stakeholders, as well as risks associated with pharmaceutical development and being a pharmaceutical company generally, along with those factors described under the heading “Risk Factors” in Clarus’ annual report on 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the SEC) on March 31, 2022, and those that are included in any of Clarus’ future filings with the SEC. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that Clarus considers immaterial, or which are unknown. It is not possible to predict or identify all such risks. Clarus’ forward-looking statements only speak as of the date they are made, and Clarus does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

     
Exhibit Number   Description
99.1   Press Release dated September 5, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  CLARUS THERAPEUTICS HOLDINGS, INC
     
     
Date: September 6, 2022 By: /s/ Robert E. Dudley
  Name: Robert E. Dudley
  Title: Chief Executive Officer

 EX-99.1 2 ea165390ex99-1_clarusthera.htm PRESS RELEASE DATED SEPTEMBER 5, 2022.

Exhibit 99.1

 

NEWS RELEASE

 

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

 

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022

NORTHBROOK, IL., September 5, 2022 – Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testosterone deficiency in men with certain medical conditions.

Clarus has filed a series of motions with the Court seeking to ensure the continuation of normal operations while on this path. Clarus believes that it has sufficient financial resources to meet its operational and financial obligations to patients, healthcare providers, suppliers, and employees through the Chapter 11 process. In addition, scaled-back efforts will continue to support commercialization of JATENZO.

“After thoroughly exploring our strategic options in a robust process conducted by the Capital Structure Advisory team at Raymond James, and in light of the extremely challenging financial markets, Clarus’ Board of Directors and its senior management team have unanimously concluded that a structured sale process represents the best possible solution for Clarus and its stakeholders,” said Dr, Robert Dudley, CEO of Clarus. “We strongly believe that JATENZO has the potential to be a valuable product for the treatment of men with testosterone deficiency and, with continued commercialization efforts, to capture increasing market share over time. Unfortunately, Clarus is no longer in a tenable financial position to provide such efforts nor remain a viable entity.”

The proposed bidding procedures, if approved by the Court, would allow interested parties to submit binding offers to acquire substantially all of Clarus’ assets (i.e., principally JATENZO and related assets), which would be purchased free and clear of Clarus’ indebtedness and certain liabilities. Interested parties could include both strategic and financial buyers, for whom substantial due diligence materials are available. 

Additional information about this process and proposed asset sale, as well as other documents related to the Chapter 11 proceedings, is available through Clarus’ claims agent, Stretto, Inc.. Clarus’ legal counsel is Goodwin Procter, LLP and Potter Anderson & Corroon LLP, and its investment banker is Raymond James & Associates, Inc. Clarus has also named Lawrence Perkins of Sierra Constellation Partners, LLC as Chief Restructuring Officer during the Chapter 11 process. Interested parties should contact Geoffrey Richards (Geoffrey.Richards@RaymondJames.com) and Simon Wein (Simon.Wein@RaymondJames.com) at Raymond James for additional information related to the auction and sale process and for access to due diligence materials. Clarus filed the voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of Delaware, Case No. 22-10845.

About Clarus Therapeutics Holdings, Inc.


Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen-based medicines. Clarus Therapeutics’ first commercial product is JATENZO (testosterone undecanoate capsules; C-III). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow Clarus on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics). 

 

 

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Clarus’ forward-looking statements in this press release include, but are not limited to, statements about Clarus’ plans to sell all of its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code; Clarus’ intention to continue operations during the Chapter 11 case; Clarus’ belief that the sale process will be in the best interest of Clarus and its stakeholders; the continued uninterrupted access to Clarus’ product during the Chapter 11 proceedings; and other statements regarding Clarus’ strategy and future operations, performance and prospects among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Clarus will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clarus’ control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on Clarus’ liquidity and results of operations; changes in Clarus’ ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and the proposed auction and asset sale; the effect of the Chapter 11 filings and proposed asset sale on Clarus’ relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the proposed asset sale; uncertainty regarding obtaining bankruptcy court approval of a sale of Clarus’ assets or other conditions to the proposed asset sale; and the timing or amount of any distributions, if any, to Clarus’ stakeholders, as well as risks associated with pharmaceutical development and being a pharmaceutical company generally, along with those factors described under the heading “Risk Factors” in Clarus’ annual report on 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the SEC) on March 31, 2022, and those that are included in any of Clarus’ future filings with the SEC. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that Clarus considers immaterial, or which are unknown. It is not possible to predict or identify all such risks. Clarus’ forward-looking statements only speak as of the date they are made, and Clarus does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc. Source: Clarus Therapeutics Holdings, Inc.

 

Media and Investor Contact

Steve Bourne

Chief Financial Officer

Sbourne@clarustherapeutics.com

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 crxt-20220831.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 crxt-20220831_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 crxt-20220831_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Aug. 31, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 31, 2022
Entity File Number 001-39802
Entity Registrant Name CLARUS THERAPEUTICS HOLDINGS, INC.
Entity Central Index Key 0001817944
Entity Tax Identification Number 85-1231852
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 555 Skokie Boulevard
Entity Address, Address Line Two Suite 340
Entity Address, City or Town Northbrook
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60062
City Area Code (847)
Local Phone Number 871-0377
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea165390-8k_clarusthera_htm.xml IDEA: XBRL DOCUMENT 0001817944 2022-08-31 2022-08-31 iso4217:USD shares iso4217:USD shares 0001817944 false 8-K 2022-08-31 CLARUS THERAPEUTICS HOLDINGS, INC. DE 001-39802 85-1231852 555 Skokie Boulevard Suite 340 Northbrook IL 60062 (847) 871-0377 false false false false true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://clarustherapeuticsholdings.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea165390-8k_clarusthera.htm crxt-20220831.xsd crxt-20220831_lab.xml crxt-20220831_pre.xml ea165390ex99-1_clarusthera.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea165390-8k_clarusthera.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea165390-8k_clarusthera.htm" ] }, "labelLink": { "local": [ "crxt-20220831_lab.xml" ] }, "presentationLink": { "local": [ "crxt-20220831_pre.xml" ] }, "schema": { "local": [ "crxt-20220831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 0, "memberStandard": 0, "nsprefix": "crxt", "nsuri": "http://clarustherapeuticsholdings.com/20220831", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea165390-8k_clarusthera.htm", "contextRef": "From2022-08-31to2022-08-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://clarustherapeuticsholdings.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea165390-8k_clarusthera.htm", "contextRef": "From2022-08-31to2022-08-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://clarustherapeuticsholdings.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001213900-22-054293-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-054293-xbrl.zip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